Zenith Health (530665)
Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹5.2 |
| Market Cap | ₹28.48 Cr |
| P/E Ratio | 39.4 |
| ROCE | 3.12% |
| ROE | 6.02% |
| Dividend Yield | 0% |
| Profit Growth | 175.86% |
| Debt/Equity | — |
| Sales Growth | 7.36% |
| 52-Week Range | ₹2.23 — ₹5.2 |
| Sector | Pharmaceuticals & Biotechnology |
| Book Value | ₹1.53 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
At ₹5.20, Zenith Health is a tiny pharmaceutical business with a market capitalisation of just ₹28 crore. Graham would tell me to start with the balance sheet and the earnings record, and neither gives me much comfort. The stock trades at 39.4 times earnings and 3.4 times book value, while the company earns only 6.02% return on equity and 3.12% on capital employed. Those returns are far below what I expect from a business with a durable moat. A pharmaceutical company should be generating excess returns on its research and brands; this one is barely covering its cost of capital.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer